Redox Pathways as Drug Targets in Microaerophilic Parasites

Trends Parasitol. 2018 Jul;34(7):576-589. doi: 10.1016/j.pt.2018.04.007. Epub 2018 May 26.

Abstract

The microaerophilic parasites Entamoeba histolytica, Trichomonas vaginalis, and Giardia lamblia jointly cause hundreds of millions of infections in humans every year. Other microaerophilic parasites such as Tritrichomonas foetus and Spironucleus spp. pose a relevant health problem in veterinary medicine. Unfortunately, vaccines against these pathogens are unavailable, but their microaerophilic lifestyle opens opportunities for specifically developed chemotherapeutics. In particular, their high sensitivity towards oxygen can be exploited by targeting redox enzymes. This review focusses on the redox pathways of microaerophilic parasites and on drugs, either already in use or currently in the state of development, which target these pathways.

Keywords: chemotherapy; microaerophilic parasites; redox pathways.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Drug Delivery Systems / trends*
  • Entamoeba histolytica / drug effects
  • Entamoeba histolytica / physiology
  • Giardia lamblia / drug effects
  • Giardia lamblia / physiology
  • Humans
  • Oxidation-Reduction*
  • Oxygen / pharmacology
  • Parasites / drug effects
  • Parasites / enzymology*
  • Trichomonas vaginalis / drug effects
  • Trichomonas vaginalis / physiology

Substances

  • Oxygen